Warts Therapeutics Market Report 2025

The warts therapeutics market size has grown steadily in recent years. It will grow from $1.96 billion in 2024 to $2.03 billion in 2025 at a compound annual growth rate (CAGR) of 3.6%. The growth in the historic period can be attributed to salicylic acid use, cryotherapy development, topical treatment evolution, surgical interventions, the emergence of immunotherapy.

The warts therapeutics market size is expected to see steady growth in the next few years. It will grow to $2.4 billion in 2029 at a compound annual growth rate (CAGR) of 4.3%. The growth in the forecast period can be attributed to precision medicine for HPV, laser therapy innovations, combination therapies, digital health solutions, and healthcare accessibility initiatives. Major trends in the forecast period include targeted antiviral therapies, gene editing research, biodegradable delivery systems, psychodermatology focus.

The wart therapeutics market is anticipated to experience growth, driven by the increasing emphasis on vaccinations for warts. Vaccination involves introducing a vaccine to develop antibodies against infections, particularly warts caused by the human papillomavirus (HPV). Therapeutic or prophylactic vaccines against HPV play a crucial role in preventing wart formation. The focus on vaccinations has led to a positive trend, as reported by the World Health Organization in July 2023, indicating a reduction in zero-dose children from 18.1 million in 2021 to 14.3 million in 2022. Furthermore, global coverage for the initial dose of the HPV vaccine in girls increased from 16% in 2021 to 21% in 2022, driving the growth of the wart therapeutics market.

The increasing accessibility of healthcare services is anticipated to drive the growth of the wart therapeutics market in the future. Healthcare services involve the provision of medical care, treatment, and support to individuals aimed at maintaining or improving their health. Wart therapeutics are utilized within these services to address and treat common skin conditions caused by the human papillomavirus (HPV). These treatments help alleviate symptoms, promote healing, and prevent the spread of warts, thereby enhancing overall well-being. For example, in December 2023, the Centers for Medicare & Medicaid Services, a US-based federal agency, reported that state and local government healthcare expenditures increased by 6.5% in 2022, building on a 6.2% rise in 2021. Furthermore, U.S. healthcare spending grew by 4.1% to $4.5 trillion in 2022, surpassing the 3.2% increase recorded in 2021. Thus, the growing accessibility of healthcare services is driving the expansion of the wart therapeutics market.

A significant trend in the wart therapeutics market is the focus on product innovation by companies striving to maintain a competitive edge. Verrica Pharmaceuticals Inc., a US-based dermatology therapeutics company, exemplifies this trend with its announcement in February 2023. The FDA accepted the resubmitted New Drug Application (NDA) for VP-102, a drug-device combination product delivering cantharidin for precise topical dosing and targeted administration to treat molluscum contagiosum, a type of wart.

Major companies in the wart therapeutics market are engaging in strategic partnerships to support clinical trials and advance research. Vial, a US-based pharmaceuticals company, partnered with Nielsen BioSciences Inc. in June 2023 to study the safety and efficacy of CANDIN for treating common warts. This collaborative approach aims to contribute to the development of new therapies and devices for wart treatment.

In March 2022, Novan Inc., a US-based pharmaceutical company, acquired EPI Health for $27.5 million. This acquisition allows Novan Inc. to improve its commercial capabilities in dermatology, broaden its product portfolio, and expedite the development of innovative skin therapies. EPI Health Inc. is a US-based company dedicated to developing innovative wart therapeutics and skincare solutions.

Major companies operating in the warts therapeutics market include GlaxoSmithKline plc, Merck & Co. Inc., Verrica Pharmaceuticals Inc., Bausch Health Companies Inc., Dr. Reddy's Laboratories Ltd, Cipla Inc., Prestige Consumer Healthcare Inc., Maruho Co. Ltd, Taro Pharmaceutical Industries Ltd, Aclaris Therapeutics Inc., Novan Inc, Scholl's Wellness Co, AIM ImmunoTech Inc., Euro Vital Pharma GmbH, Koninklijke Utermöhlen NV, Nielsen BioSciences Inc., RXi Pharmaceuticals, Phio Pharmaceuticals Corp., MedCara Pharmaceuticals, KinoPharma Inc., pHion Therapeutics, Compound W, Duofilm, Curad Mediplast, Emblation Ltd.

North America was the largest region in the warts therapeutics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the warts therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the warts therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Wart therapeutics refer to medical drugs and treatments designed to exert therapeutic effects in addressing the skin condition known as warts, caused by the human papillomavirus (HPV). These therapeutics are utilized for the treatment of various wart types affecting the hands, face, and feet.

The primary types of warts in wart therapeutics include common warts, genital warts, flat warts, and others. Common warts are small, raised skin growths typically found on the hands or fingers. Treatment approaches for common warts involve physical destruction, immunomodulation, and chemical destruction. Wart therapeutics are employed in diverse healthcare settings, including hospitals, homecare, specialty clinics, and others.

The warts therapeutics market research report is one of a series of new reports that provides warts therapeutics market statistics, including the warts therapeutics industry global market size, regional shares, competitors with an warts therapeutics market share, detailed warts therapeutics market segments, market trends, and opportunities, and any further data you may need to thrive in the warts therapeutics industry. This warts therapeutics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The warts therapeutics market consists of sales of therapeutic drugs such as 5-fluorouracil, benzalkonium, glutaraldehyde, cryotherapy, or podophyllin. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.